Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04186403 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)
A Phase 2 study of Borderline Personality Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 2
- Development phase
- 201
- Enrollment target
- 1
- Study location
NCT04186403 is a Phase 2 study of Borderline Personality Disorder that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 201 participants, above the 95-participant average among 16 other Borderline Personality Disorder trials with a reported enrollment target (112% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04186403, a Phase 2 study of Borderline Personality Disorder, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 201 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the safety and tolerability of brexpiprazole in the treatment of adults with borderline personality disorder.
Conditions Studied
Interventions
- DRUG Brexpiprazole
Study Locations (1)
New York
- For additional information regarding sites, contact 844-687-8522 - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2020-01-13 |
| Est. Completion | 2021-09-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04186403
The ClinicalTrials.gov registry entry for NCT04186403 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 95-participant average among 16 other Borderline Personality Disorder trials with a reported enrollment target (112% higher). The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Borderline Personality Disorder appearing as the primary indexed condition, and to 1 intervention - of which Brexpiprazole is the first listed.
NCT04186403 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04186403 about?
NCT04186403 is a clinical study titled "Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)". This study evaluates the safety and tolerability of brexpiprazole in the treatment of adults with borderline personality disorder.
What is the current status of trial NCT04186403?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 201 participants. The study started on 2020-01-13. Estimated completion is 2021-09-22.
What conditions does trial NCT04186403 study?
This clinical trial studies the following conditions: Borderline Personality Disorder.
What interventions are being tested in trial NCT04186403?
The interventions under investigation include: Brexpiprazole (DRUG).
Who is sponsoring clinical trial NCT04186403?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04186403 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Borderline Personality Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MDMA in Borderline Personality Disorder
RECRUITING · Phase 2
-
Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder
RECRUITING · Phase 2
-
Treatment of Suicidal Women With Borderline Personality Disorder
COMPLETED · Phase 2
-
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
RECRUITING · NA
-
Cognitive Reappraisal Training for Borderline Personality (BPD)
RECRUITING · NA
-
Treatment of Borderline Personality Disorder With rTMS
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.